Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

Role of Epigenetic Modulation for the Treatment of Sarcoma

(2013) Gregory M. Cote et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?

(2012) Sabrina Ehnert et al.   BMC Medicine

Appraising the Current Role of Chemotherapy for the Treatment of Sarcoma

(2011) David R. D'Adamo   SEMINARS IN ONCOLOGY

Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells

(2010) Cao Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin

(2010) Luke A. Wittenburg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy

(2010) Erik R. Sampson et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

(2010) Andelko Hrzenjak et al.   Molecular Cancer

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

(2009) G. Lopez et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylase Inhibitors Reverse SS18-SSX-Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial Sarcoma

(2008) J. M. Lubieniecka et al.   CANCER RESEARCH